AI-Powered Glucose Monitoring: Zydus Lifesciences Launches DiasensTM and GlucoLiveTM to Transform Diabetes Care in India

In partnership with

Speak your prompts. Get better outputs.

The best AI outputs come from detailed prompts. But typing long, context-rich prompts is slow - so most people don't bother.

Wispr Flow turns your voice into clean, ready-to-paste text. Speak naturally into ChatGPT, Claude, Cursor, or any AI tool and get polished output without editing. Describe edge cases, explain context, walk through your thinking - all at the speed you talk.

Millions of people use Flow to give AI tools 10x more context in half the time. 89% of messages sent with zero edits.

Works system-wide on Mac, Windows, iPhone, and now Android (free and unlimited on Android during launch).

Try Wispr Flow free →

In a significant step toward improving diabetes management in India, Zydus Lifesciences Limited has launched two advanced continuous glucose monitoring (CGM) devices—Diasens™ and GlucoLive™. These next-generation devices integrate artificial intelligence (AI) with real-time health monitoring to provide patients and healthcare professionals with continuous insights into blood glucose levels.

The launch represents a major advancement in digital healthcare technology, particularly in a country where diabetes has become one of the most pressing public health challenges.

Addressing India’s Growing Diabetes Burden

India currently faces a severe diabetes crisis. According to research conducted by the Indian Council of Medical Research (ICMR), more than 101 million adults in the country are living with diabetes, while another 136 million are considered pre-diabetic. This places India among the nations with the highest diabetes burden globally.

Diabetes is also one of the leading causes of Chronic Kidney Disease (CKD) in the country. Studies suggest that nearly 25–40 percent of CKD patients have a history of diabetes. With rising cases of kidney failure and organ transplantation, continuous glucose monitoring has become increasingly important for patients suffering from chronic diseases.

Traditionally, diabetes monitoring has relied on episodic tests such as finger-prick blood glucose checks or HbA1c tests conducted every three to six months in laboratories. While these methods provide useful data, they often fail to capture real-time fluctuations in blood sugar levels throughout the day and night.

The introduction of Diasens™ and GlucoLive™ aims to bridge this gap by providing continuous monitoring and AI-powered insights.

Next-Generation CGM Technology

The newly launched devices represent a significant upgrade over many existing glucose monitoring systems. Unlike traditional CGM devices that rely on Near Field Communication (NFC) technology and require manual scanning, Diasens™ and GlucoLive™ automatically stream glucose readings to a patient’s smartphone.

The devices generate glucose readings every three minutes, offering a comprehensive and continuous view of a patient’s blood sugar patterns. This automated streaming eliminates the need for manual scanning, making the monitoring process far more convenient for patients.

Another key advantage is the ability to capture overnight glucose data. Nighttime fluctuations often go unnoticed with conventional monitoring methods, but continuous monitoring allows patients and doctors to identify hidden risks such as nocturnal hypoglycemia.

Artificial Intelligence for Smarter Healthcare

Artificial intelligence plays a central role in the functionality of the new CGM devices. The AI system analyzes glucose data to detect patterns, predict potential risks, and generate insights that help both patients and healthcare providers make informed decisions.

For example, the AI analytics engine can:

• Identify rising or falling glucose trends

• Detect dangerous hypoglycemic or hyperglycemic episodes

• Correlate glucose fluctuations with food intake and physical activity

• Generate personalized recommendations for lifestyle changes

This data-driven approach allows patients to better understand how their diet, exercise, and daily habits affect their glucose levels.

Digital Integration Through the GoodFlip™ App

To further enhance the patient experience, Zydus has partnered with Digicare Health Solutions Private Limited (TatvaCare™), a digital healthcare company. The CGM devices integrate with TatvaCare’s proprietary mobile platform, the GoodFlip app.

The app acts as a comprehensive digital health ecosystem that brings together multiple healthcare services in one platform.

Key features of the GoodFlip™ app include:

• AI-powered glucose report analysis

• Personalized diet and fitness guidance

• Online doctor consultations

• Diagnostic lab booking services

• Secure medical record storage

• Real-time alerts for abnormal glucose levels

This integration creates a connected healthcare environment where patients, caregivers, and doctors can interact seamlessly.

Remote Monitoring for Doctors

One of the most important aspects of the new system is the clinician dashboard. This feature allows healthcare professionals to monitor patients remotely using real-time glucose data.

Doctors can track trends, analyze historical data, and make timely treatment adjustments without requiring frequent hospital visits. Remote monitoring is especially beneficial for high-risk patients such as those with diabetes complications, kidney disease, or post-transplant conditions.

By enabling early detection of potential problems, continuous monitoring can significantly reduce the risk of medical emergencies.

A Step Toward Preventive Healthcare

Speaking about the launch, Sharvil Patel, Managing Director of Zydus Lifesciences, emphasized the company’s commitment to patient-centric healthcare innovation.

According to Patel, the new CGM systems strengthen the company’s companion diagnostics portfolio and aim to improve quality of life for patients suffering from chronic diseases. The AI-powered devices allow individuals to access critical glucose information in real time through their smartphones, simplifying diabetes monitoring and control.

Transforming Chronic Disease Management

The integration of AI, continuous monitoring, and digital healthcare platforms marks an important shift in how chronic diseases are managed. Instead of relying solely on periodic medical tests, patients and doctors now have access to real-time health insights.

Continuous glucose monitoring not only helps manage diabetes more effectively but also plays a crucial role in preventing complications such as heart disease, kidney failure, and nerve damage.

With India facing an ever-increasing burden of diabetes and related conditions, innovations like Diasens™ and GlucoLive™ could significantly improve long-term health outcomes.

Conclusion

The launch of Diasens™ and GlucoLive™ by Zydus Lifesciences Limited represents a major milestone in the evolution of diabetes care in India. By combining AI-powered analytics, real-time glucose monitoring, and digital health integration, these devices offer a smarter and more proactive approach to managing chronic diseases.

As healthcare systems around the world increasingly adopt digital and AI-driven solutions, technologies like continuous glucose monitoring are expected to play a vital role in shaping the future of personalized and preventive healthcare.